JOHNSON & JOHNSON is 236.7x more valuable than IDEAYA Biosciences, Inc. by market capitalization ($574.10 B vs $2.42 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | IDYA | JNJ |
|---|---|---|
| Market cap | $2.42 B | $574.10 B |
| US-listed rank | #1966 | #20 |
| Revenue (latest FY) | $218.71M | $94.19B |
| Net income (latest FY) | -$113.70M | $26.80B |
| Net margin | -52.0% | 28.5% |
| P/E (trailing FY) | - | 21.4 |
| SEC filings | 477 | 984 |
JOHNSON & JOHNSON is 236.7x more valuable than IDEAYA Biosciences, Inc. by market capitalization ($574.10 B vs $2.42 B).
In their latest fiscal years, IDEAYA Biosciences, Inc. reported $218.71M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: IDEAYA Biosciences, Inc. and JOHNSON & JOHNSON, or browse the full rankings.